Evidence map›Paper›PMID 41703071›Full record

ArticleEMBO reports2026

Gim3 buffers and potentiates de novo mutations that affect fluconazole susceptibility in yeast.

Mohammed T Tawfeeq, Dimitrios Konstantinidis, Ana Lucia Rocha Iraizos, Wouter Van Genechten, Jolien Vreys, Lieselotte Vermeersch, Karin Voordeckers, Patrick Van Dijck, Kevin J Verstrepen

Abstract read
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammed T TawfeeqVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, Leuven, 3001, Belgium.ORCID 0000-0001-9504-5284
Dimitrios KonstantinidisVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, Leuven, 3001, Belgium.ORCID 0000-0002-2134-6823
Ana Lucia Rocha IraizosVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, Leuven, 3001, Belgium.ORCID 0009-0006-3043-7993
Wouter Van GenechtenLaboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, 3001, Belgium.ORCID 0000-0002-8562-8029
Jolien VreysLaboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, 3001, Belgium.ORCID 0000-0001-5310-336X
Lieselotte VermeerschVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, Leuven, 3001, Belgium.ORCID 0000-0001-5789-2220
Karin VoordeckersVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, Leuven, 3001, Belgium.ORCID 0000-0001-6397-840X
Patrick Van DijckLaboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, 3001, Belgium. patrick.vandijck@kuleuven.be.ORCID 0000-0002-1542-897X
Kevin J VerstrepenVIB Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, Leuven, 3001, Belgium. kevin.verstrepen@kuleuven.be.ORCID 0000-0002-3077-6219

Funding

EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA) 101065618Fonds Wetenschappelijk Onderzoek (FWO) 11H1823NFonds Wetenschappelijk Onderzoek (FWO) 11L0423NFonds Wetenschappelijk Onderzoek (FWO) 1283423NFWO large-scale research infrastructure grant I011820NKU Leuven C1 grant C16/23/007
6 · The paper itself

Abstract

Gim3 is an evolutionarily conserved component of the prefoldin chaperone complex, involved in protein folding. We previously found that GIM3 genetically interacts with many de novo mutations in Saccharomyces cerevisiae. Removing GIM3 from mutagenized S. cerevisiae cells significantly affected the fitness effect of mutations. This indicates that Gim3 might change the evolutionary impact of de novo mutations by either buffering (hiding) or potentiating (increasing) their phenotypic effects, depending on the environmental or genetic context. Here, we investigated Gim3's role in shaping the evolutionary fate of de novo mutations under fluconazole stress, an antifungal drug used to combat fungal infections. Applying both strong and moderate fluconazole stress in the presence or absence of GIM3 revealed that Gim3 potentiates fluconazole susceptibility (resistance and tolerance) by enabling mutations to have immediate phenotypic effects. Deleting GIM3 reduced growth in fluconazole in most mutants, indicating that GIM3 could be a promising target for new antifungal therapies against drug-resistant infections. Importantly, Gim3 also modulates fluconazole susceptibility of the fungal pathogen Nakaseomyces glabratus, further highlighting Gim3's role in fluconazole resistance and tolerance.

Indexed as

Antifungal AgentsDrug Resistance, FungalFluconazoleMolecular ChaperonesMutationSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsMicrobial Sensitivity TestsPhenotypeAntifungal AgentsFluconazoleMolecular ChaperonesSaccharomyces cerevisiae ProteinsDrug SusceptibilityEvolvabilityGim3Mutational Robustness

Identifiers

PMID41703071
PMCPMC13022404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.